Peter Marks

Peter Marks

Company: FDA

Job title: Director, CBER


Virtual: Rare Disease Gene Therapy Development: Where Has It Been and Where Is It Going? 8:30 am

Comparing progress in rare disorders in vivo with developments seen in CAR-T and ex vivo cell modified gene therapies Where are the current bottlenecks for gene therapy approvals? Addressing FDA’s outlook for gene therapy in 2022Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.